Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Community sentiment
Where do you think PBLS is heading?
1 month
6 months
12 months
5 years
Keep private notes on PBLS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
PBLS vs S&P 500 · rebased to 100
—(S&P 500 +10.2% / yr)▼ 5.2% total
Compare:
Early cycleMid cycleLate cycleRecession
Background shading marks the US business-cycle phase at each point in time — early, mid and late expansion, then recession— so you can see which economic backdrop each move happened in. Recessions are NBER-official; expansion sub-phases are ActaClear's editorial dating.
Lines:
Overlay:
Live market
delayed ≤15 min$28.88
▲ 9.56%
- Market cap
- —
- Enterprise value
- —
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $34.47
- 52-wk low
- $24.51
- Beta
- —
- Shares out
- —
What this company does
Not yet available for PBLS.
Key risks
Not yet available for PBLS.
4.7
of 10
ActaClear Score
Neutral
#442 of 531 in Pharmaceutical Preparations
+0.1 · 8d
Profitability·25%
—
Growth·15%
—
Value·20%
3.8
Quality·20%
—
Momentum·20%
5.5
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (531 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 27, 2026.